Who We Are

Grounded in more than 20 years of ADC expertise, Byondis is evolving the field with novel payload platforms, advanced masking technology, and optimized linker and conjugation strategies. Our approach enables the development of ADCs with superior efficacy, duration of response, and safety to improve clinical outcomes and bring hope to patients facing difficult-to-treat cancers.

Operating from state-of-the-art facilities in Nijmegen, the Netherlands, our end-to-end capabilities, spanning pre-clinical and clinical R&D, GMP manufacturing, and regulatory engagement, enable efficient development from discovery to commercial launch.